Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BRITISH BIOTECH IND FOR STEM CELL PROTECTOR BB-10010 APPROVED

Executive Summary

BRITISH BIOTECH IND FOR STEM CELL PROTECTOR BB-10010 APPROVED Nov. 30, Chief Financial Officer James Noble told the annual Robertson, Stephens medical conference in New York City Dec. 1. "We'll be putting forward clinical trials at Indiana [University Medical Center] very shortly, I hope in the next couple of weeks," Noble continued. BB-10010 is a "genetically engineered variant" of "a natural stem cell protector in bone marrow," LD78, Noble said. British Biotechnology is pursuing "two different clinical programs" for the compound: stem cell protection and stem cell mobilization.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS025430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel